Novo Holdings Procures Leading Pharma Solutions Firm, Catalent

Novo Holdings has announced intentions for the procurement of Catalent for just over $16 billion to develop their production proficiencies.   

Novo Holdings is an investment company that manages the assets of the Novo Nordisk Foundation, focusing on long-term investments in life sciences, including healthcare and biotechnology.  

Catalent is a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.  

A successful acquisition will see Novo Holdings obtain all Catalent’s outstanding shares.  

The firm unveiled that they are planning to complete the acquisition by the end of 2024, subject to receiving acceptance from necessary regulatory bodies and Catalent’s stockholders. 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.